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Therapeutics that disrupt the p53-MDM2 interaction showpromise for cancer treatment but surprisingly have
different biological outcomes. A study by Enge et al. in this issue of Cancer Cell shows that the ability of
MDM2 to target hnRNP K for degradation contributes to the decision to induce apoptosis rather than
cell-cycle arrest.The activities of the p53 tumor suppressor
must be carefully controlled in normal
cells. If present at high levels, as occurs
in response to DNA damage, hypoxia,
oncogene activation, or other types of
stress, p53 initiates a cell death, cell-cycle
arrest, or senescence program. Since
these activities prevent damaged cells
from dividing, tumor cells often gain a
growth advantage by mutating p53 to
bypass these terminal phenotypes. p53
functions as a transcriptional activator to
induce the expression of genes such as
CDKN1A (p21), which regulates cell-cycle
arrest and senescence, and BAX, Noxa,
and PUMA, which regulate apoptosis.
p53’s choice is dependent on the levels
of p53, tissue type, and the presence of
other death signals (Vousden and Lu,
2002). A better understanding of how this
choice is made will contribute to better
treatment of cancers, as death of a tumor
cell is preferred to arrest of that cell.
At least two negative regulators,MDM2
and MDM4, are critical inhibitors of p53
in vivo (Iwakuma and Lozano, 2003). Dele-
tion of these genes in mice leads to p53-
dependent embryonic lethal phenotypes.
The regulation of p53 activity is complex,
as p53 can transcriptionally induce its
own negative regulator MDM2, but not
MDM4. MDM2 is an E3 ubiquitin ligase
that targets p53 and other substrates to
the proteasome for degradation. MDM2
is often present at high levels in tumors
with wild-type p53 and likely serves as
an alternate mechanism to disrupt the
p53 pathway in developing cancer cells.
However, MDM2 targets numerous other
substrates, particularly when present at
elevated levels or when it cannot interact
with p53 (possibly due to posttranslational
modifications of p53) (Iwakuma and Loz-
ano, 2003). These MDM2 substrateshave numerous roles in determining cell
fate.
Therapeutic agents for the treatment of
cancers are being developed to capitalize
on the cell-cycle arrest or apoptotic
response of the p53 pathway induced by
disruption of the p53-MDM2 interaction
(Vazquez et al., 2008). Compounds that
bind to MDM2 and inhibit its ability to
bind to or regulate p53 as well as agents
that associate with and activate p53
are in preclinical development. Nutlins,
benzodiazepines, spiro-oxindoles, and
quinolinols bind to MDM2 and inhibit its
p53 association, whereas HL198C is an
inhibitor of MDM2 ubiquitin ligase activity
(Vazquez et al., 2008). Treatment of cells
that express wild-type p53 with any of
these compounds induces the stabiliza-
tion and transcriptional activation of p53,
resulting in cell-cycle arrest or apoptosis.
Another small molecule called RITA binds
p53, inhibits p53-MDM2 interaction, and
induces p53-dependent transcription
and apoptosis. Although RITA can also
alter the cell cycle, it appears to primarily
induce apoptosis (Issaeva et al., 2004). A
surprising finding has been that although
these agents target the same pathway,
different biological outcomes can be at-
tained. Determining why one compound
induces apoptosis while another results
in cell-cycle arrest in a specific tumor cell
is the focus of a manuscript by Selivanova
and colleagues in this issue (Enge et al.,
2009).
To examine the molecular mechanisms
of RITA’s activity in an unbiased manner,
Enge et al. first obtained gene expression
patterns for HCT116 cells, which express
wild-type p53, and their isogenic clone
that lacks p53. Initial expression arrays
revealed some differences in gene
expression between HCT116 cells withCancer Celland without p53, suggesting minor effects
of p53 at basal levels. RITA treatment
induced significant changes in gene
expression in a p53-dependent manner.
Interestingly, activation of p53 promi-
nently induced proapoptotic targets but
only slightly induced p21 and other cell-
cycle arrest genes in this setting. Since
RITA binds p53 specifically as compared
to nutlins, which bind MDM2, the authors
postulated that the unfettered MDM2
determines the preference for apoptosis.
MDM2, in addition to ubiquitinating
p53, also regulates the stability of other
proteins, some of which are in the p53
response pathway (Iwakuma and Lozano,
2003). Heterogeneous nuclear ribonu-
cleoprotein K (hnRNP K) is one MDM2
target (Moumen et al., 2005). As part of
the hnRNP complex, hnRNP K was origi-
nally identified for its role in mRNA biogen-
esis and maturation, but it is most noted
for its involvement in transcription and
chromatin remodeling. Upon DNA
damage, hnRNP K levels rise due to
reduced association with MDM2 (Mou-
men et al., 2005). hnRNP K is also re-
cruited with p53 to the promoters of p53
transcriptional target genes. p53-depen-
dent transcriptional activation and the
resulting cell-cycle arrest, following DNA
damage, is impaired in cells depleted of
hnRNP K. Moreover, hnRNP K-depleted
cells are unable to effectively mount a
p53-dependent transcriptional response
to nutlin treatment, leading to the conclu-
sion that hnRNP K is required for p53-
mediated transcription (Moumen et al.,
2005). However, it was unclear whether
hnRNP K is necessary for the transcription
of all or only a subset of p53 target genes.
Enge et al. (2009) now show that RITA
treatment increases MDM2 levels and
MDM2-hnRNP K association, resulting in15, March 3, 2009 ª2009 Elsevier Inc. 161
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MDM2 binds and targets p53 (mottled to show degradation) for proteasome-mediated degradation. The
small molecule RITA binds p53 and disrupts the p53-MDM2 interaction. The released MDM2 then targets
hnRNP K (mottled) for proteasomal degradation, dampening expression of the cell-cycle inhibitor p21
but not the expression of proapoptotic genes. The triangle represents other transcription factors that
cooperate with p53 to induce transcription of apoptotic genes.MDM2-mediated degradation of hnRNP K
and, consequently, reduced transcrip-
tional upregulation of p21, but not the
apoptotic gene Noxa (Figure 1). Nutlin,
on the other hand, did not alter hnRNP K
levels and preferentially induced p21
over Noxa transcription. In addition to a
reduction in p21 transcription, p21 half-
life was also decreased following RITA
treatment. Since MDM2 has been re-
ported to induce p21 degradation inde-
pendent of its ubiquitin ligase activity and
independent of p53 by facilitating p21
association with the proteasome (Jin
et al., 2003; Zhang et al., 2004), MDM2
was postulated to be responsible for the
decreased p21 protein levels after RITA
treatment. Together, the results suggest
that RITA preferentially induces an
apoptotic response in part due to
MDM2-mediated degradation of p21 and
hnRNP K, which reduces transcription of
p21 and permits transcription of Noxa. In
contrast, nutlins, by binding to MDM2,162 Cancer Cell 15, March 3, 2009 ª2009 Elprevent hnRNP K degradation, allowing
for efficient transcription of p21, which in-
duces cell-cycle arrest. Notably, hnRNP K
was necessary for p21 transcription but
appeared dispensable for Noxa tran-
scription. Lastly, overexpression of p21
experimentally dampened the apoptotic
response of cells treated with RITA, and
depletion of p21 enhanced apoptosis in
nutlin-treated cells, further documenting
an important role of p21 in the decision
between cell-cycle arrest and apoptosis.
In summary, the work of Enge et al.
shows that when it cannot bind p53,
MDM2 is able to target hnRNP K, the
depletion of which decreases levels of
p21 and pushes cells toward an apoptotic
response (Figure 1). Thus, in this scenario,
MDM2 is forced to help p53 eliminate
tumor cells. MDM2 likely has other targets
that assist in determining the cellular
response, as it binds a multitude of other
proteins (Iwakuma and Lozano, 2003). In
contrast, if MDM2 is bound to p53, thensevier Inc.p53 cannot function and cells have a
growth advantage. Many other studies
have shown that elevated levels of
MDM2 are oncogenic; additional studies
will be necessary to understand the
mechanisms behind the different cellular
outcomes following disruption of the
p53-MDM2 interaction. Importantly, since
MDM2 also regulates mutant p53 levels
resulting in gain-of-function phenotypes,
the ability of RITA to bind mutant p53
must be examined, and caution may
need to be exercised to treat only tumors
with wild-type p53 (Terzian et al., 2008).
These results suggest that p53 does not
function alone in making the choice
between apoptosis and cell-cycle arrest.
Treatment of tumors with drugs that
decrease the expression of p53 targets
such as p21 may cooperate with drugs
such as nutlins to swing the balance
toward cell death.
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